| scholarly article | Q13442814 |
| P50 | author | Linzhao Cheng | Q71770338 |
| Zhaohui Ye | Q39188888 | ||
| Chi V. Dang | Q47824561 | ||
| P2093 | author name string | Alison R Moliterno | |
| Donna M Williams | |||
| Jerry L Spivak | |||
| Prashant Mali | |||
| Sarah Dowey | |||
| Huichun Zhan | |||
| Yoon-Young Jang | |||
| P2860 | cites work | Disease-specific induced pluripotent stem cells | Q24641981 |
| Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins | Q24653753 | ||
| A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms | Q27851467 | ||
| Induced pluripotent stem cell lines derived from human somatic cells | Q27860597 | ||
| Induction of pluripotent stem cells from adult human fibroblasts by defined factors | Q27860967 | ||
| A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 | ||
| Reprogramming of human somatic cells to pluripotency with defined factors | Q28262710 | ||
| Ex vivo culture of cord blood CD34+ cells expands progenitor cell numbers, preserves engraftment capacity in nonobese diabetic/severe combined immunodeficient mice, and enhances retroviral transduction efficiency | Q73299265 | ||
| The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera | Q80050823 | ||
| Myeloproliferative disorders | Q81943280 | ||
| Human induced pluripotent stem cells free of vector and transgene sequences | Q29547624 | ||
| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 | ||
| Induced pluripotent stem cells from a spinal muscular atrophy patient | Q29614340 | ||
| Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons | Q29616199 | ||
| A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
| Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 | ||
| Generation of induced pluripotent stem cells using recombinant proteins | Q29619162 | ||
| piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells | Q29619409 | ||
| JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms | Q33383709 | ||
| Identification of an acquired JAK2 mutation in polycythemia vera | Q33947635 | ||
| Generation of human induced pluripotent stem cells from dermal fibroblasts | Q34588555 | ||
| Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency | Q34771507 | ||
| Effects and safety of granulocyte colony-stimulating factor in healthy volunteers | Q35679682 | ||
| Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression | Q35848857 | ||
| Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice | Q36658043 | ||
| Notch signaling activation in human embryonic stem cells is required for embryonic, but not trophoblastic, lineage commitment | Q36742076 | ||
| Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens | Q37009717 | ||
| Generation of induced pluripotent stem cells from human blood | Q37209041 | ||
| Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells | Q37287210 | ||
| Trophoblast differentiation defect in human embryonic stem cells lacking PIG-A and GPI-anchored cell-surface proteins | Q39653706 | ||
| Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts | Q39977218 | ||
| Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro | Q40537295 | ||
| Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera | Q40746470 | ||
| Hb F production of endogenous colonies of polycythemia vera | Q40989641 | ||
| Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon | Q41815168 | ||
| Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. | Q44854570 | ||
| Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice | Q46832173 | ||
| The genetic basis of myeloproliferative disorders | Q46892252 | ||
| A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies | Q47735198 | ||
| Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation. | Q50767115 | ||
| A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. | Q51768323 | ||
| Definitive proof for direct reprogramming of hematopoietic cells to pluripotency. | Q54475445 | ||
| Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation. | Q54774945 | ||
| P4510 | describes a project that uses | iCB5 | Q54897221 |
| iMPD183.C1 | Q54897606 | ||
| iMPD183.C10 | Q54897607 | ||
| iMPD183.C11 | Q54897608 | ||
| iMPD183.C2 | Q54897609 | ||
| iMPD183.C3 | Q54897610 | ||
| iMPD183.C5 | Q54897611 | ||
| iMPD183.C6 | Q54897612 | ||
| iMPD183.C7 | Q54897613 | ||
| iMPD183.C8 | Q54897614 | ||
| iMPD562.C2 | Q54897615 | ||
| iMPD562.C3 | Q54897616 | ||
| iBM5 | Q54897183 | ||
| iBM9 | Q54897184 | ||
| P433 | issue | 27 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| cell line | Q21014462 | ||
| Human Induced Pluripotent Stem Cells | Q88981775 | ||
| P304 | page(s) | 5473-5480 | |
| P577 | publication date | 2009-10-01 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders | |
| P478 | volume | 114 |
| Q89919060 | A comparison of hepato-cellular in vitro platforms to study CYP3A4 induction |
| Q28477450 | A defined, feeder-free, serum-free system to generate in vitro hematopoietic progenitors and differentiated blood cells from hESCs and hiPSCs |
| Q35200170 | A facile method to establish human induced pluripotent stem cells from adult blood cells under feeder-free and xeno-free culture conditions: a clinically compliant approach |
| Q34320565 | A practical and efficient cellular substrate for the generation of induced pluripotent stem cells from adults: blood-derived endothelial progenitor cells |
| Q26853179 | Advances in cellular technology in the hematology field: What have we learned so far? |
| Q41225238 | Alcohol Increases Liver Progenitor Populations and Induces Disease Phenotypes in Human IPSC-Derived Mature Stage Hepatic Cells |
| Q26775122 | An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs |
| Q34314350 | An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells |
| Q39173212 | Application of Induced Pluripotent Stem Cell Technology to the Study of Hematological Diseases |
| Q38154616 | Applications of human hematopoietic stem cells isolated and expanded from different tissues in regenerative medicine |
| Q37823231 | Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease |
| Q37742101 | Approaches for immunological tolerance induction to stem cell-derived cell replacement therapies |
| Q57792732 | Biliary Atresia Relevant Human Induced Pluripotent Stem Cells Recapitulate Key Disease Features in a Dish. |
| Q37052835 | Blood cell-derived induced pluripotent stem cells free of reprogramming factors generated by Sendai viral vectors |
| Q74440275 | Brain cells made from urine |
| Q34463138 | Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. |
| Q37832530 | Cardiomyocyte differentiation of pluripotent stem cells and their use as cardiac disease models |
| Q38141509 | Cellular reprogramming of human peripheral blood cells |
| Q45157881 | Chondrogenic differentiation of induced pluripotent stem cells from osteoarthritic chondrocytes in alginate matrix |
| Q33930452 | Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases |
| Q37954229 | Concise review: Cord blood banking, transplantation and induced pluripotent stem cell: success and opportunities |
| Q33409483 | Congenital amegakaryocytic thrombocytopenia iPS cells exhibit defective MPL-mediated signaling |
| Q26746544 | Current Management of Alcoholic Hepatitis and Future Therapies |
| Q38372922 | Current advances in the generation of human iPS cells: implications in cell-based regenerative medicine. |
| Q37997154 | Current applications of human pluripotent stem cells: possibilities and challenges |
| Q38034129 | Current status of drug screening and disease modelling in human pluripotent stem cells. |
| Q35533599 | De novo generation of HSCs from somatic and pluripotent stem cell sources |
| Q37792339 | Delivery of nucleic acid therapeutics by genetically engineered hematopoietic stem cells |
| Q28750802 | Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes |
| Q37338044 | Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency. |
| Q35676075 | Development of hematopoietic stem and progenitor cells from human pluripotent stem cells |
| Q33894805 | Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells |
| Q37214753 | Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells. |
| Q26866409 | Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application |
| Q38059468 | Disease modelling using induced pluripotent stem cells: status and prospects |
| Q39501841 | Disease-corrected hepatocyte-like cells from familial hypercholesterolemia-induced pluripotent stem cells |
| Q42863198 | Distinct iPS Cells Show Different Cardiac Differentiation Efficiency |
| Q36140488 | Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells |
| Q35031911 | Early intervention for spinal cord injury with human induced pluripotent stem cells oligodendrocyte progenitors |
| Q38938334 | Efficient and allele-specific genome editing of disease loci in human iPSCs |
| Q35620068 | Efficient and scalable expansion of human pluripotent stem cells under clinically compliant settings: a view in 2013 |
| Q36138514 | Efficient derivation and genetic modifications of human pluripotent stem cells on engineered human feeder cell lines |
| Q34550486 | Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells |
| Q34373911 | Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions |
| Q34738075 | Efficient generation of integration-free ips cells from human adult peripheral blood using BCL-XL together with Yamanaka factors |
| Q33420698 | Efficient generation of megakaryocytes from human induced pluripotent stem cells using food and drug administration-approved pharmacological reagents |
| Q30502017 | Efficient generation of nonhuman primate induced pluripotent stem cells |
| Q34162877 | Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells |
| Q38706487 | Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures |
| Q41021257 | Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone. |
| Q37799363 | Engineering blood vessels using stem cells: innovative approaches to treat vascular disorders |
| Q37523278 | Epigenetic regulation of NANOG by miR-302 cluster-MBD2 completes induced pluripotent stem cell reprogramming |
| Q33687796 | Establishment of induced pluripotent stem cells from normal B cells and inducing AID expression in their differentiation into hematopoietic progenitor cells. |
| Q90749981 | Experimental Modeling of Myeloproliferative Neoplasms |
| Q37562037 | Extensive ex vivo expansion of functional human erythroid precursors established from umbilical cord blood cells by defined factors |
| Q39764925 | Feeder-free derivation of induced pluripotent stem cells from human immature dental pulp stem cells |
| Q37763190 | Generation and genetic modification of induced pluripotent stem cells |
| Q27301480 | Generation of Functional Cardiomyocytes from Efficiently Generated Human iPSCs and a Novel Method of Measuring Contractility |
| Q36379316 | Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells. |
| Q34078669 | Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes |
| Q37255037 | Generation of glycosylphosphatidylinositol anchor protein-deficient blood cells from human induced pluripotent stem cells |
| Q28478987 | Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells |
| Q38117548 | Generation of iPS cells from normal and malignant hematopoietic cells |
| Q60221837 | Generation of induced pluripotent stem cells from human cord blood cells with only two factors: Oct4 and Sox2 |
| Q34320340 | Generation of induced pluripotent stem cells using site-specific integration with phage integrase |
| Q37131138 | Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression |
| Q37408786 | Generation of patient-specific induced neuronal cells using a direct reprogramming strategy |
| Q38014779 | Generation of red blood cells from human embryonic/induced pluripotent stem cells for blood transfusion |
| Q35249192 | Genes inducing iPS phenotype play a role in hepatocyte survival and proliferation in vitro and liver regeneration in vivo. |
| Q38113338 | Genome editing of human pluripotent stem cells to generate human cellular disease models |
| Q39239599 | Genome editing: a robust technology for human stem cells |
| Q92394646 | Genomic Instability of iPSCs and Challenges in Their Clinical Applications |
| Q38945910 | Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications |
| Q42857534 | Globin phenotype of erythroid cells derived from human induced pluripotent stem cells |
| Q38105298 | Glucose metabolism, hyperosmotic stress, and reprogramming of somatic cells. |
| Q36948090 | Hair follicle: a novel source of multipotent stem cells for tissue engineering and regenerative medicine |
| Q38116641 | Hematopoietic cell differentiation from embryonic and induced pluripotent stem cells. |
| Q39177276 | Hematopoietic cells as sources for patient-specific iPSCs and disease modeling |
| Q35001593 | Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood |
| Q28533511 | Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients |
| Q51832273 | Human amniotic epithelial cell feeder layers maintain human iPS cell pluripotency via inhibited endogenous microRNA-145 and increased Sox2 expression. |
| Q37289093 | Human amniotic epithelial cell feeder layers maintain iPS cell pluripotency by inhibiting endogenous DNA methyltransferase 1. |
| Q39605721 | Human cord blood applications in cell therapy: looking back and look ahead |
| Q30577389 | Human finger-prick induced pluripotent stem cells facilitate the development of stem cell banking. |
| Q37693597 | Human iPS cell-based therapy: considerations before clinical applications |
| Q37414043 | Human induced pluripotent cells resemble embryonic stem cells demonstrating enhanced levels of DNA repair and efficacy of nonhomologous end-joining |
| Q38258436 | Human induced pluripotent stem cell and nanotechnology-based therapeutics |
| Q34284032 | Human induced pluripotent stem cells can reach complete terminal maturation: in vivo and in vitro evidence in the erythropoietic differentiation model. |
| Q37316328 | Human induced pluripotent stem cells from basic research to potential clinical applications in cancer |
| Q42509303 | Human menstrual blood-derived mesenchymal cells as a cell source of rapid and efficient nuclear reprogramming. |
| Q40387172 | Human neural progenitors derived from integration-free iPSCs for SCI therapy |
| Q35930059 | Human-induced pluripotent stem cells generated from intervertebral disc cells improve neurologic functions in spinal cord injury |
| Q34251675 | Human-induced pluripotent stem cells: in quest of clinical applications |
| Q91897504 | Human-relevant preclinical in vitro models for studying hepatobiliary development and liver diseases using induced pluripotent stem cells |
| Q36666422 | Immunological applications of stem cells in type 1 diabetes |
| Q33414617 | Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients |
| Q36208256 | Implications of aneuploidy for stem cell biology and brain therapeutics |
| Q37005193 | In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells |
| Q35834934 | In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. |
| Q26775061 | Induced Pluripotency and Gene Editing in Disease Modelling: Perspectives and Challenges |
| Q26750579 | Induced Pluripotent Stem Cell as a New Source for Cancer Immunotherapy |
| Q26996540 | Induced pluripotent stem cell (iPSCs) and their application in immunotherapy |
| Q28083057 | Induced pluripotent stem cell potential in medicine, specifically focused on reproductive medicine |
| Q37359244 | Induced pluripotent stem cell reprogramming by integration-free Sendai virus vectors from peripheral blood of patients with craniometaphyseal dysplasia |
| Q37988757 | Induced pluripotent stem cell research: a revolutionary approach to face the challenges in drug screening. |
| Q51919490 | Induced pluripotent stem cell technology for the study of human disease. |
| Q84595149 | Induced pluripotent stem cells (iPSCs)--a new era of reprogramming |
| Q37976707 | Induced pluripotent stem cells and personalized medicine: current progress and future perspectives |
| Q37995010 | Induced pluripotent stem cells and severe combined immunodeficiency: merely disease modeling or potentially a novel cure? |
| Q38039220 | Induced pluripotent stem cells and their potential for basic and clinical sciences |
| Q38358569 | Induced pluripotent stem cells and their use in cardiac and neural regenerative medicine |
| Q37581014 | Induced pluripotent stem cells as a cellular model for studying Down Syndrome |
| Q26865689 | Induced pluripotent stem cells as a disease modeling and drug screening platform |
| Q37055318 | Induced pluripotent stem cells as a next-generation biomedical interface |
| Q35088519 | Induced pluripotent stem cells for modelling human diseases |
| Q35028209 | Induced pluripotent stem cells for regenerative cardiovascular therapies and biomedical discovery |
| Q35923410 | Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells |
| Q34231818 | Induced pluripotent stem cells--opportunities for disease modelling and drug discovery |
| Q35037783 | Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery |
| Q37801268 | Induced pluripotent stem cells: developmental biology to regenerative medicine |
| Q37824869 | Induced pluripotent stem cells: emerging techniques for nuclear reprogramming |
| Q37392636 | Induced pluripotent stem cells: origins, applications, and future perspectives |
| Q34303709 | Induced pluripotent stem cells: the new patient? |
| Q37462880 | Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors |
| Q37088296 | Induction of pluripotency in bone marrow mononuclear cells via polyketal nanoparticle-mediated delivery of mature microRNAs |
| Q34431170 | Investigating human disease using stem cell models |
| Q53293069 | Leukemia stem cells. |
| Q38562633 | Liver engraftment potential of hepatic cells derived from patient-specific induced pluripotent stem cells |
| Q38222504 | Mechanotransduction: tuning stem cells fate |
| Q38017612 | Mesodermal and hematopoietic differentiation from ES and iPS cells |
| Q39306963 | Modeling Cancer with Pluripotent Stem Cells |
| Q57490090 | Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells |
| Q92570903 | Modeling blood diseases with human induced pluripotent stem cells |
| Q93341559 | Modeling myeloid malignancies with patient-derived iPSCs |
| Q39328610 | Modeling the process of human tumorigenesis. |
| Q26750384 | Mucosal-associated invariant T cells from induced pluripotent stem cells: A novel approach for modeling human diseases |
| Q41849202 | Murine iPSC-Derived Macrophages as a Tool for Disease Modeling of Hereditary Pulmonary Alveolar Proteinosis due to Csf2rb Deficiency |
| Q37737385 | Neurodegenerative disease-specific induced pluripotent stem cell research |
| Q36945734 | New frontier in regenerative medicine: site-specific gene correction in patient-specific induced pluripotent stem cells |
| Q36374130 | New lessons learned from disease modeling with induced pluripotent stem cells |
| Q39094722 | Niemann-Pick type C1 patient-specific induced pluripotent stem cells display disease specific hallmarks |
| Q35215395 | No evidence for clonal selection due to lentiviral integration sites in human induced pluripotent stem cells. |
| Q34619318 | Nuclear reprogramming strategy modulates differentiation potential of induced pluripotent stem cells |
| Q47442360 | Organ-On-A-Chip Platforms: A Convergence of Advanced Materials, Cells, and Microscale Technologies |
| Q35030912 | Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting |
| Q38786566 | Patient-derived induced pluripotent stem cells in cancer research and precision oncology. |
| Q36928346 | Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia |
| Q33910479 | Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome |
| Q37783804 | Pluripotent stem cell-derived natural killer cells for cancer therapy |
| Q37891178 | Pluripotent stem cells and reprogrammed cells in farm animals. |
| Q37857709 | Potential clinical applications for human pluripotent stem cell-derived blood components |
| Q37772900 | Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types |
| Q21560913 | Production of embryonic and fetal-like red blood cells from human induced pluripotent stem cells |
| Q38012401 | Promise and challenges of human iPSC-based hematologic disease modeling and treatment |
| Q38031618 | Prospects and challenges of reprogrammed cells in hematology and oncology. |
| Q33895201 | Qualitative and quantitative comparison of the proteome of erythroid cells differentiated from human iPSCs and adult erythroid cells by multiplex TMT labelling and nanoLC-MS/MS |
| Q56523742 | RETRACTED: Generation of induced pluripotent stem cells using skin fibroblasts from patients with myocardial infarction under feeder-free conditions |
| Q36761531 | RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells |
| Q36810424 | Rapid and efficient reprogramming of human fetal and adult blood CD34+ cells into mesenchymal stem cells with a single factor. |
| Q65002709 | Recent Updates on Induced Pluripotent Stem Cells in Hematological Disorders. |
| Q34175573 | Reconstructing blood from induced pluripotent stem cells |
| Q42772160 | Reprogrammed astrocytes with old 'memories' blossom into region-specific neurons |
| Q42236206 | Reprogrammed mouse astrocytes retain a "memory" of tissue origin and possess more tendencies for neuronal differentiation than reprogrammed mouse embryonic fibroblasts |
| Q37994281 | Reprogramming cellular identity for regenerative medicine |
| Q35172462 | Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells |
| Q34034432 | Reprogramming of T cells from human peripheral blood |
| Q28730417 | Residual expression of the reprogramming factors prevents differentiation of iPSC generated from human fibroblasts and cord blood CD34+ progenitors |
| Q92994162 | Robust and highly efficient hiPSC generation from patient non-mobilized peripheral blood-derived CD34+ cells using the auto-erasable Sendai virus vector |
| Q38052148 | Roles of reactive oxygen species in the fate of stem cells. |
| Q35238279 | Safeguarding nonhuman primate iPS cells with suicide genes. |
| Q42606543 | Scalable expansion of human induced pluripotent stem cells in the defined xeno-free E8 medium under adherent and suspension culture conditions |
| Q35585501 | Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1 |
| Q26747006 | Site-Specific Genome Engineering in Human Pluripotent Stem Cells |
| Q35525329 | Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease |
| Q41999327 | Sleeping Beauty transposon-based system for cellular reprogramming and targeted gene insertion in induced pluripotent stem cells. |
| Q45991787 | Somatic cells with a heavy mitochondrial DNA mutational load render induced pluripotent stem cells with distinct differentiation defects. |
| Q28082268 | Stem Cells: Potential Therapy for Neonatal Injury? |
| Q27028106 | Stem cell sources for vascular tissue engineering and regeneration |
| Q39623344 | Successful differentiation to T cells, but unsuccessful B-cell generation, from B-cell-derived induced pluripotent stem cells |
| Q37642100 | Technical challenges in using human induced pluripotent stem cells to model disease |
| Q39063423 | Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation |
| Q34032363 | The elite and stochastic model for iPS cell generation: multilineage-differentiating stress enduring (Muse) cells are readily reprogrammable into iPS cells |
| Q37270428 | The modern primitives: applying new technological approaches to explore the biology of the earliest red blood cells |
| Q38030196 | The role of induced pluripotent stem cells in research and therapy of primary immunodeficiencies |
| Q37598422 | The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders |
| Q34353627 | Thinking outside the liver: induced pluripotent stem cells for hepatic applications |
| Q64914010 | Transient c-Src Suppression During Endodermal Commitment of Human Induced Pluripotent Stem Cells Results in Abnormal Profibrotic Cholangiocyte-Like Cells. |
| Q43094467 | Variation in hematopoietic potential of induced pluripotent stem cell lines |
| Q26751506 | hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine |
| Q55398510 | iPS Cells-The Triumphs and Tribulations. |
Search more.